Additional file 1 of CD200 in dentate gyrus improves depressive-like behaviors of mice through enhancing hippocampal neurogenesis via alleviation of microglia hyperactivation
Creators: name: Chen, Xi
name: Cui, Qian-Qian
name: Hu, Xiao-Hai
name: Ye, Jian
name: Liu, Zi-Cun
name: Mei, Yuan-Xi
name: Wang, Fang
name: Hu, Zhuang-Li
name: Chen, Jian-Guo
Publisher: name: figshare
Year: 2023
Subjects: subject: Medicine
subject: Neuroscience
subject: Sociology
subject: FOS: Sociology
subject: Immunology
subject: FOS: Clinical medicine
subject: Mental Health

description: Additional file 1: Figure S1. mRNA expression of CD200 in different brain regions after exposure to CSDS. A Analysis of CD200 mRNA expression in the mPFC region of mice after CSDS. B Analysis of CD200 mRNA expression in the Hip region of mice after CSDS. C Analysis of CD200 mRNA expression in the DG region of mice after CSDS. D Analysis of CD200 mRNA expression in the CA1 region of mice after CSDS. E Analysis of CD200 mRNA expression in the CA3 region of mice after CSDS. Data are expressed as mean ± SEM. *P &lt; 0.05; ***P &lt; 0.001. Figure S2. Injection of CD200Fc into the lateral ventricle alleviates CSDS-induced depressive-like behavior. A Experimental timelines for CSDS procedure, CD200Fc administration and behavioral testing. B The social interaction ratio in the SIT of control and CSDS mice with exogenous CD200Fc injection. C, D The immobility time in the TSTand FSTof control and CSDS mice with exogenous CD200Fc injection. E The total distance in the OFT of control and CSDS mice with exogenous CD200Fc injection. Data are expressed as mean ± SEM. *P &lt; 0.05; **P &lt; 0.01; ***P &lt; 0.001. Figure S3. Overexpression of CD200 in DG facilitates the expression of anti-inflammatory factors after CSDS. A Experimental timelines for CSDS procedure, AAV–CD200 stereotaxical injection and behavioral testing. B Analysis of mRNA levels of Arg-1, YM-1, IL-4, TNF-α, IL-6, and IL-1β after injection of AAV–CD200 virus to the DG region in susceptible mice. Data are expressed as mean ± SEM. *P &lt; 0.05; **P &lt; 0.01. Figure S4. CD200 increases the expression of BDNF in the DG brain region of susceptible mice. A Experimental timelines for CSDS procedure, CD200Fc administration and behavioral testing. B Representative immunostaining for BDNFin the DG of control and CSDS group after CD200Fc administration. Scale bars: 80 μm. C The fluorescence intensity of BDNF in the DG of control and CSDS group after CD200Fc administration. Data are expressed as mean ± SEM. *P &lt; 0.05; ***P &lt; 0.001. Figure S5. CD200Fc ameliorates adult hippocampal neurogenesis impairment in susceptible mice. A Experimental timelines for CSDS procedure, CD200Fc administration and behavioral testing. B Representative immunostaining for BrdU/DCX in the DG of control and CSDS group after CD200Fc administration. Scale bars: 40 μm. C, D Statistical graph for the number of BrdU+ and BrdU+ DCX+ cells in the DG of control and CSDS group after CD200Fc administration. Data are expressed as mean ± SEM. *P &lt; 0.05; **P &lt; 0.01; ***P &lt; 0.001. Figure S6. Raw blot data for Fig. 1G, 3C and 4D. Table S1. Sequences of primers for qPCR. Table S2. Statistical analysis for each figure.